发明申请
US20050244470A1 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
有权
含有酪氨酸激酶抑制剂的持续释放眼内植入物及相关方法
- 专利标题： Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
- 专利标题（中）： 含有酪氨酸激酶抑制剂的持续释放眼内植入物及相关方法
-
申请号： US10837361申请日： 2004-04-30
-
公开(公告)号： US20050244470A1公开(公告)日： 2005-11-03
- 发明人: Patrick Hughes , Thomas Malone , Gerald De Vries , Jeffrey Edelman , Joan-En Chang-Lin , Jane Shiah , Thierry Nivaggioli
- 申请人： Patrick Hughes , Thomas Malone , Gerald De Vries , Jeffrey Edelman , Joan-En Chang-Lin , Jane Shiah , Thierry Nivaggioli
- 申请人地址： US CA Irvine
- 专利权人： Allergan, Inc.
- 当前专利权人： Allergan, Inc.
- 当前专利权人地址： US CA Irvine
- 主分类号： A61K9/00
- IPC分类号： A61K9/00 ; A61K9/20 ; A61K31/00 ; A61K31/404 ; A61F2/00
摘要：
Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.